Perspectives in gynecologic oncology -- Third European Conference.
Horiot
Jean-Claude
JC
Centre de Lutte Contre le Cancer, GF Leclerc, Dijon 21000, France. horiotjc@dijon.fnclcc.fr
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D000068258:Bevacizumab; D005260:Female; D006176:Gynecology / Q000639:trends*; D006801:Humans; D008495:Medical Oncology / Q000639:trends*; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D018579:Patient Selection; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D011494:Protein Kinases / Q000187:drug effects / Q000378:metabolism; D016032:Randomized Controlled Trials as Topic; D020123:Sirolimus / Q000494:pharmacology / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D000068258:Bevacizumab; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus